As a result, patients will eat less food because they wont feel as hungry
For example, in liraglutide trials, 24.7% of participants reported nausea at week 4, but this dropped to 14.7% by week 8 and just 5.5% by week 56
The peptides potential extends beyond dermatology, with investigations purporting possible roles in wound healing, tissue regeneration, and anti-cellular aging
Medicaid pharmacy and therapeutics committees reviewing Zepbound evaluate this evidence when making formulary decisions
Common gastrointestinal effects impact most users during the initial weeks of treatment
Gastrointestinal Upset Though rare, some individuals may experience mild bloating, cramps, or stomach discomfort